Icandra

Metformin Hydrochloride / Vildagliptin, the active ingredient in Icandra, is a Biguanide / DPP‑4 inhibitor presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adult patients by improving glycaemic control. GNH USA supplies Icandra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icandra is used to manage hyperglycaemia in the type 2 diabetes pathway.

Type 2 diabetes mellitus: improves blood glucose control when combined with diet and exercise. Adjunct therapy: used alongside lifestyle modifications to achieve target HbA1c levels. Glycaemic control: helps lower fasting and post‑prandial glucose concentrations.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhoea. - Headache: mild to moderate intensity. - Metallic taste: transient alteration in taste perception. - Upper respiratory tract symptoms: mild cough or sore throat. - Skin rash: mild erythema or pruritus.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic complication. - Severe hypoglycaemia: especially when combined with insulin or sulfonylureas. - Pancreatitis: acute inflammation of the pancreas. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Renal impairment: worsening kidney function leading to drug accumulation.

Before initiating Icandra, consider the following precautions.

Renal function monitoring: assess eGFR and adjust dose in renal impairment. Hepatic status: evaluate liver function tests prior to use. Lactic acidosis risk: avoid in patients with conditions predisposing to hypoxia. Pregnancy and lactation: safety not established; use only if benefits outweigh risks. Elderly patients: start at lower dose and monitor for adverse effects. Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Icandra may interact with several medicines; monitoring is advised.

Major Interactions (Avoid): - Renal failure (eGFR <30 mL/min): contraindicated due to risk of accumulation. - Iodinated contrast agents: may precipitate lactic acidosis; discontinue before imaging. - Concurrent insulin or sulfonylureas: increased risk of severe hypoglycaemia.

Moderate Interactions (Monitor Closely): - Cimetidine: can raise Vildagliptin plasma levels. - Beta‑blockers: may mask hypoglycaemia symptoms. - Diuretics: may affect renal clearance of Metformin.